BACKGROUND: Carcinogenic transformation of white blood cells during hematopoiesis leads to the development of leukemia, a cancer characterized by incompetent immune cells and a disruption of normal bone marrow function. Leukemias are diverse in type, affected population, prognosis, and treatment regimen, yet a common theme in leukemia is the dysregulated metabolism of leukemic cells and leukemic stem cells with respect to their noncancerous counterparts. RECENT FINDINGS: In this review, we highlight current findings that elucidate metabolic traits unique to the four major types of leukemia, which confer carcinogenic survival but can be potentially exploited for therapeutic intervention. These metabolic features can work in conjunction with or be independent of unique aspects of the bone marrow microenvironment that can also influence cell survival and proliferation, thus sustaining carcinogenesis. CONCLUSION: Deepening our understanding of the interactions of leukemias with their niche environments in vivo will inform future treatments for leukemia, particularly for those that are refractive to tyrosine kinase inhibitors and other therapeutic mainstays.
BACKGROUND:Carcinogenic transformation of white blood cells during hematopoiesis leads to the development of leukemia, a cancer characterized by incompetent immune cells and a disruption of normal bone marrow function. Leukemias are diverse in type, affected population, prognosis, and treatment regimen, yet a common theme in leukemia is the dysregulated metabolism of leukemic cells and leukemic stem cells with respect to their noncancerous counterparts. RECENT FINDINGS: In this review, we highlight current findings that elucidate metabolic traits unique to the four major types of leukemia, which confer carcinogenic survival but can be potentially exploited for therapeutic intervention. These metabolic features can work in conjunction with or be independent of unique aspects of the bone marrow microenvironment that can also influence cell survival and proliferation, thus sustaining carcinogenesis. CONCLUSION: Deepening our understanding of the interactions of leukemias with their niche environments in vivo will inform future treatments for leukemia, particularly for those that are refractive to tyrosine kinase inhibitors and other therapeutic mainstays.
Authors: Vionnie W C Yu; Rushdia Z Yusuf; Toshihiko Oki; Juwell Wu; Borja Saez; Xin Wang; Colleen Cook; Ninib Baryawno; Michael J Ziller; Eunjung Lee; Hongcang Gu; Alexander Meissner; Charles P Lin; Peter V Kharchenko; David T Scadden Journal: Cell Date: 2016-11-17 Impact factor: 41.582
Authors: Francesca Alvarez-Calderon; Mark A Gregory; Catherine Pham-Danis; Deborah DeRyckere; Brett M Stevens; Vadym Zaberezhnyy; Amanda A Hill; Lelisa Gemta; Amit Kumar; Vijay Kumar; Michael F Wempe; Daniel A Pollyea; Craig T Jordan; Natalie J Serkova; Douglas K Graham; James DeGregori Journal: Clin Cancer Res Date: 2014-12-29 Impact factor: 12.531
Authors: Marko Skrtić; Shrivani Sriskanthadevan; Bozhena Jhas; Marinella Gebbia; Xiaoming Wang; Zezhou Wang; Rose Hurren; Yulia Jitkova; Marcela Gronda; Neil Maclean; Courteney K Lai; Yanina Eberhard; Justyna Bartoszko; Paul Spagnuolo; Angela C Rutledge; Alessandro Datti; Troy Ketela; Jason Moffat; Brian H Robinson; Jessie H Cameron; Jeffery Wrana; Connie J Eaves; Mark D Minden; Jean C Y Wang; John E Dick; Keith Humphries; Corey Nislow; Guri Giaever; Aaron D Schimmer Journal: Cancer Cell Date: 2011-11-15 Impact factor: 31.743
Authors: Radana Karlíková; Jitka Široká; David Friedecký; Edgar Faber; Marcela Hrdá; Kateřina Mičová; Iveta Fikarová; Alžběta Gardlo; Hana Janečková; Ivo Vrobel; Tomáš Adam Journal: J Proteome Res Date: 2016-08-09 Impact factor: 4.466
Authors: Daniel J Ceradini; Anita R Kulkarni; Matthew J Callaghan; Oren M Tepper; Nicholas Bastidas; Mark E Kleinman; Jennifer M Capla; Robert D Galiano; Jamie P Levine; Geoffrey C Gurtner Journal: Nat Med Date: 2004-07-04 Impact factor: 53.440
Authors: Adele K Fielding; Susan M Richards; Rajesh Chopra; Hillard M Lazarus; Mark R Litzow; Georgina Buck; I Jill Durrant; Selina M Luger; David I Marks; Ian M Franklin; Andrew K McMillan; Martin S Tallman; Jacob M Rowe; Anthony H Goldstone Journal: Blood Date: 2006-10-10 Impact factor: 22.113
Authors: Andrew M Intlekofer; Raymond G Dematteo; Sriram Venneti; Lydia W S Finley; Chao Lu; Alexander R Judkins; Ariën S Rustenburg; Patrick B Grinaway; John D Chodera; Justin R Cross; Craig B Thompson Journal: Cell Metab Date: 2015-07-23 Impact factor: 31.373
Authors: Ali S Alqahtani; Mostafa M Ghorab; Fahd A Nasr; Mohammad Z Ahmed; Abdullah A Al Mishari; Sabry M Attia; Muhammad Farooq Khan Journal: Int J Mol Sci Date: 2022-04-25 Impact factor: 6.208